Generation of Fas-independent CD4+ cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide

Leuk Res. 2002 Mar;26(3):317-21. doi: 10.1016/s0145-2126(01)00119-9.

Abstract

In the majority of Ph+ALL patients, p190 bcr-abl fusion protein is generated in the Philadelphia chromosome. The fusion protein may serve as a leukemia antigen because it is not expressed in normal cells and hardly in any other malignancy. From a healthy donor, we have established a p190 bcr-abl fusion peptide-specific CD4+ cytotoxic T-cell clone, activation of which depends on HLA-DRB1*1501. This T-cell clone has a strong cytotoxic activity against autologus MoDCs pulsed with e1a2 peptide and its cytotoxicity is not mediated by Fas/Fas ligand or perforin pathway. Success in establishment of the p190 bcr-abl fusion peptide-specific T-cell clone encourages us to develop a new approach to an effective immunotherapy for Ph+ALL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antibodies, Monoclonal / pharmacology
  • Antigens, CD / analysis
  • CD4 Antigens / analysis*
  • Cell Survival
  • Clone Cells
  • Cytotoxicity, Immunologic*
  • Flow Cytometry
  • Fusion Proteins, bcr-abl / analysis*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Lymphocyte Activation
  • Molecular Sequence Data
  • Peptide Fragments / chemical synthesis
  • Peptide Fragments / immunology
  • Reference Values
  • T-Lymphocytes / immunology*
  • T-Lymphocytes, Cytotoxic / immunology*
  • fas Receptor / physiology*

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • CD4 Antigens
  • Peptide Fragments
  • fas Receptor
  • Fusion Proteins, bcr-abl